Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
Screening recommendations, triple therapy and more—here are insights into the upcoming ACR guideline for the care and treatment of patients with lupus nephritis.
Many rheumatologists may not be trained to properly identify the signs of skin disease in patients with dark skin, but in this ACR Convergence session, experts provide practical guidance for diagnosis.
Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.
Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.